Evidence map›Paper›PMID 40606062›Full record

ArticleOpen forum infectious diseases2025

Assessment of Failures of Long-acting Cabotegravir and Rilpivirine in a Real-world Treatment Setting.

Nicholas Yared, Smitha Gudipati, Shannon Payne, Indira Brar

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. [Early virological failure with long-acting cabotegravir/rilpivirine: description of two cases].Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Nicholas YaredHenry Ford Health, Department of Medicine, Division of Infectious Diseases, Detroit, Michigan, USA.
Smitha GudipatiHenry Ford Health, Department of Medicine, Division of Infectious Diseases, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-0760-8268
Shannon PayneHenry Ford Health, Department of Medicine, Division of Infectious Diseases, Detroit, Michigan, USA.ORCID https://orcid.org/0009-0001-7708-595X
Indira BrarHenry Ford Health, Department of Medicine, Division of Infectious Diseases, Detroit, Michigan, USA.ORCID https://orcid.org/0000-0002-0568-6457

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fifty-eight people with HIV switched to long-acting cabotegravir and rilpivirine in a real-world clinic setting had higher discontinuation rates because of virologic failure, side effects, or nonadherence compared to clinical trials. Archived proviral genotype testing before long-active cabotegravir and rilpivirine switch should be considered to reduce virologic failure risk.

Indexed as

cabotegravirHIVrilpivirinevirologic failure

Identifiers

PMID40606062
PMCPMC12216902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.